229 related articles for article (PubMed ID: 26598040)
1. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care.
Pantano Nde P; Paiva BS; Hui D; Paiva CE
J Pain Symptom Manage; 2016 Feb; 51(2):270-7. PubMed ID: 26598040
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.
Laird BJ; Kaasa S; McMillan DC; Fallon MT; Hjermstad MJ; Fayers P; Klepstad P
Clin Cancer Res; 2013 Oct; 19(19):5456-64. PubMed ID: 23938289
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
[TBL] [Abstract][Full Text] [Related]
4. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
6. Relationship of nutritional status and inflammation with survival in patients with advanced cancer in palliative care.
Souza Cunha M; Wiegert EVM; Calixto-Lima L; Oliveira LC
Nutrition; 2018; 51-52():98-103. PubMed ID: 29625409
[TBL] [Abstract][Full Text] [Related]
7. Palliative stenting for oesophagogastric cancer: tumour and host factors and prognosis.
Park JH; Woodley N; McMillan DC; Glen P
BMJ Support Palliat Care; 2019 Sep; 9(3):332-339. PubMed ID: 29574423
[TBL] [Abstract][Full Text] [Related]
8. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
[TBL] [Abstract][Full Text] [Related]
9. Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?
Walsh SM; Casey S; Kennedy R; Ravi N; Reynolds JV
J Surg Oncol; 2016 Jun; 113(7):732-7. PubMed ID: 27004839
[TBL] [Abstract][Full Text] [Related]
10. Prognostication in advanced cancer: a study examining an inflammation-based score.
Partridge M; Fallon M; Bray C; McMillan D; Brown D; Laird B
J Pain Symptom Manage; 2012 Aug; 44(2):161-7. PubMed ID: 22732417
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
12. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
13. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
Ishizuka M; Nagata H; Takagi K; Kubota K
Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
[TBL] [Abstract][Full Text] [Related]
14. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study.
Imaoka H; Mizuno N; Hara K; Hijioka S; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutsumi H; Fujiyoshi T; Sato T; Shimizu Y; Niwa Y; Yamao K
Pancreas; 2016 Feb; 45(2):211-7. PubMed ID: 26495775
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer.
Jeong JH; Lim SM; Yun JY; Rhee GW; Lim JY; Cho JY; Kim YR
Oncology; 2012; 83(5):292-9. PubMed ID: 22964877
[TBL] [Abstract][Full Text] [Related]
17. Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host.
Park JH; Watt DG; Roxburgh CS; Horgan PG; McMillan DC
Ann Surg; 2016 Feb; 263(2):326-36. PubMed ID: 25575264
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
[TBL] [Abstract][Full Text] [Related]
19. High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy.
Chen P; Fang M; Wan Q; Zhang X; Song T; Wu S
Oncotarget; 2017 Nov; 8(59):99861-99870. PubMed ID: 29245945
[TBL] [Abstract][Full Text] [Related]
20. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
